PolyPid
Most recent annual filing: 2026-02-25
- D-PLEX₁₀₀ MAA filing3Q 2026D-PLEX₁₀₀ MAA filing, 3Q 2026, notable
- D-PLEX₁₀₀ filing2H 2026D-PLEX₁₀₀ filing, 2H 2026, notable
- D-PLEX₁₀₀ PDUFA dateNov 28, 2026D-PLEX₁₀₀ PDUFA date, Nov 28, 2026, thesis-defining
- D-PLEX₁₀₀ commercial launch1Q 2027D-PLEX₁₀₀ commercial launch, 1Q 2027, routine
- D-PLEX₁₀₀ EU decision2H 2027D-PLEX₁₀₀ EU decision, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (2 active programs)
OncoPLEX
Technology platforms
PLEX · ImmunoGenesis
Proprietary polymer-lipid matrix controlled-release delivery platform enabling localized, prolonged drug release at the target site over days to months; applicable to small molecules, peptides, antibodies, and nucleic acid-based drugs; disease areas include surgical site infection prevention, oncology, inflammation, and pain.
Kynatrix
Expanded drug delivery technology platform unifying PolyPid's drug delivery capabilities beyond the original PLEX technology, including ultra long-acting subcutaneous delivery; first application is a GLP-1 receptor agonist program for metabolic diseases including obesity and diabetes.
Targets: GLP-1 receptor
Biotech Distilled coverage (2)
- 2026-08-13 UPDATE: PolyPid (PYPD) - The Going-Concern Paragraph Is Gone 🔒 Paid
- 2026-08-03 PolyPid Ltd. (PYPD) — Scientific Deep Dive for D-PLEX₁₀₀ and the Kynatrix Platform 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.